CytomX Therapeutics Inc
NASDAQ:CTMX

Watchlist Manager
CytomX Therapeutics Inc Logo
CytomX Therapeutics Inc
NASDAQ:CTMX
Watchlist
Price: 2.275 USD 2.94%
Market Cap: 358.4m USD

Intrinsic Value

CTMX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one CTMX stock under the Base Case scenario is 0.285 USD. Compared to the current market price of 2.275 USD, CytomX Therapeutics Inc is Overvalued by 87%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CTMX Intrinsic Value
0.285 USD
Overvaluation 87%
Intrinsic Value
Price
Base Case Scenario

Valuation History
CytomX Therapeutics Inc

Valuation History Unavailable

Historical valuation for CTMX cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%
Compare CTMX to

Fundamental Analysis

Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about CTMX?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about CytomX Therapeutics Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
CytomX Therapeutics Inc

Current Assets 86.6m
Cash & Short-Term Investments 79.9m
Receivables 2m
Other Current Assets 4.8m
Non-Current Assets 11.9m
PP&E 9.3m
Intangibles 1.5m
Other Non-Current Assets 1.1m
Efficiency

Free Cash Flow Analysis
CytomX Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
CytomX Therapeutics Inc

Revenue
147.6m USD
Operating Expenses
-111.6m USD
Operating Income
36m USD
Other Expenses
5.6m USD
Net Income
41.6m USD
Fundamental Scores

CTMX Profitability Score
Profitability Due Diligence

CytomX Therapeutics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional ROIC
ROIC is Increasing
Exceptional 1-Year Revenue Growth
29/100
Profitability
Score

CytomX Therapeutics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

CTMX Solvency Score
Solvency Due Diligence

CytomX Therapeutics Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
50/100
Solvency
Score

CytomX Therapeutics Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CTMX Price Targets Summary
CytomX Therapeutics Inc

Wall Street analysts forecast CTMX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CTMX is 5.61 USD with a low forecast of 3.535 USD and a high forecast of 8.4 USD.

Lowest
Price Target
3.535 USD
55% Upside
Average
Price Target
5.61 USD
147% Upside
Highest
Price Target
8.4 USD
269% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

CytomX Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for CTMX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

CTMX Insider Trading
Buy and sell transactions by insiders

CTMX News

What is the Intrinsic Value of one CTMX stock?

The intrinsic value of one CTMX stock under the Base Case scenario is 0.285 USD.

Is CTMX stock undervalued or overvalued?

Compared to the current market price of 2.275 USD, CytomX Therapeutics Inc is Overvalued by 87%.

Back to Top